Medifast (MED)
Medifast on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on NYSE, classified by the SEC as miscellaneous food preparations & kindred products.
1.1M
Short interest
settlement 2026-09-30
7.3
Days to cover
-12.7 days vs prior
65.0%
Short share of volume
2026-10-09
5
Fails to deliver
settlement 2026-09-14
Mon 2 Nov
Next earnings
estimated date
$1.2M
Insider flow, 90 days
8 buys, 2 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in MED is 1,053,225 shares, down 829,696 shares over the last month. Over the last 48 readings it ranged from 1,053,225 shares (30 September 2026) to 2,338,927 shares (15 September 2025). The latest reading sits at the bottom of that range. At the reported average volume of 144K shares a day that is 7.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/med" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 1,053,225 | -43.4% | 144,284 | 7.30 |
| 2026-09-15 | 1,862,070 | -1.1% | 93,002 | 20.02 |
| 2026-08-31 | 1,882,921 | +3.2% | 124,599 | 15.11 |
| 2026-08-14 | 1,824,259 | +22.9% | 245,780 | 7.42 |
| 2026-07-31 | 1,484,483 | -9.5% | 162,017 | 9.16 |
| 2026-07-15 | 1,639,608 | +5.0% | 174,167 | 9.41 |
| 2026-06-30 | 1,561,657 | -27.6% | 423,124 | 3.69 |
| 2026-06-15 | 2,155,853 | -0.9% | 140,556 | 15.34 |
| 2026-05-29 | 2,175,625 | -0.5% | 214,199 | 10.16 |
| 2026-05-15 | 2,186,673 | +7.6% | 234,277 | 9.33 |
| 2026-04-30 | 2,031,979 | -6.1% | 154,047 | 13.19 |
| 2026-04-15 | 2,164,087 | +5.3% | 232,828 | 9.29 |
| 2026-03-31 | 2,055,809 | +0.9% | 300,284 | 6.85 |
| 2026-03-13 | 2,036,788 | +0.7% | 273,350 | 7.45 |
| 2026-02-27 | 2,021,760 | -2.9% | 326,234 | 6.20 |
| 2026-02-13 | 2,081,194 | +3.7% | 211,435 | 9.84 |
| 2026-01-30 | 2,006,688 | -7.1% | 205,540 | 9.76 |
| 2026-01-15 | 2,160,105 | +9.5% | 258,797 | 8.35 |
| 2025-12-31 | 1,972,978 | -1.1% | 308,731 | 6.39 |
| 2025-12-15 | 1,993,975 | +7.5% | 277,217 | 7.19 |
| 2025-11-28 | 1,854,480 | -10.0% | 219,539 | 8.45 |
| 2025-11-14 | 2,061,127 | +1.0% | 180,747 | 11.40 |
| 2025-10-31 | 2,040,495 | -2.1% | 173,707 | 11.75 |
| 2025-10-15 | 2,085,375 | -0.3% | 122,736 | 16.99 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of MED volume is 65.0%, up 0.3 points over the last five sessions. Over the last 30 readings it ranged from 18.0% (22 September 2026) to 75.7% (17 September 2026). The latest reading is 12.8 points above the 30-session average of 52.2%, on 29K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 19K | 29K | 65.0% | 0 |
| 2026-10-08 | 16K | 40K | 40.8% | 0 |
| 2026-10-07 | 20K | 38K | 53.0% | 963 |
| 2026-10-06 | 14K | 44K | 32.6% | 0 |
| 2026-10-05 | 11K | 20K | 54.6% | 0 |
| 2026-10-02 | 22K | 34K | 64.7% | 0 |
| 2026-10-01 | 34K | 59K | 57.1% | 0 |
| 2026-09-30 | 42K | 73K | 57.9% | 0 |
| 2026-09-29 | 18K | 60K | 29.9% | 0 |
| 2026-09-28 | 13K | 47K | 28.4% | 0 |
| 2026-09-25 | 71K | 109K | 65.4% | 0 |
| 2026-09-24 | 15K | 30K | 50.6% | 0 |
| 2026-09-23 | 29K | 58K | 50.0% | 0 |
| 2026-09-22 | 4K | 22K | 18.0% | 0 |
| 2026-09-21 | 55K | 84K | 65.0% | 0 |
| 2026-09-18 | 22K | 38K | 56.8% | 0 |
| 2026-09-17 | 35K | 46K | 75.7% | 0 |
| 2026-09-16 | 37K | 53K | 69.5% | 0 |
| 2026-09-15 | 17K | 26K | 67.5% | 0 |
| 2026-09-14 | 12K | 23K | 53.3% | 0 |
| 2026-09-11 | 29K | 41K | 70.0% | 0 |
| 2026-09-10 | 10K | 20K | 48.8% | 16 |
| 2026-09-09 | 13K | 31K | 40.2% | 25 |
| 2026-09-08 | 16K | 31K | 52.1% | 0 |
| 2026-09-04 | 10K | 18K | 57.4% | 0 |
| 2026-09-03 | 28K | 48K | 57.6% | 0 |
| 2026-09-02 | 42K | 114K | 36.5% | 1,156 |
| 2026-09-01 | 22K | 50K | 44.3% | 822 |
| 2026-08-31 | 28K | 58K | 49.0% | 11 |
| 2026-08-28 | 20K | 36K | 55.3% | 300 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in MED is 5 shares, down 161 shares over the last settlement date. Over the last 30 readings it ranged from 5 shares (17 July 2026) to 664,590 shares (22 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 5 | $12.04 | $60 |
| 2026-09-11 | 166 | $12.05 | $2K |
| 2026-09-08 | 79 | $12.63 | $998 |
| 2026-09-04 | 17 | $12.54 | $213 |
| 2026-09-03 | 445 | $12.67 | $6K |
| 2026-08-27 | 1,177 | $12.22 | $14K |
| 2026-08-24 | 88,000 | $11.95 | $1.1M |
| 2026-08-21 | 215 | $11.62 | $2K |
| 2026-08-20 | 590 | $11.58 | $7K |
| 2026-08-11 | 310 | $12.09 | $4K |
| 2026-07-30 | 20 | $9.64 | $193 |
| 2026-07-29 | 10 | $9.75 | $98 |
| 2026-07-28 | 1,111 | $9.91 | $11K |
| 2026-07-27 | 2,709 | $9.68 | $26K |
| 2026-07-23 | 22 | $9.76 | $215 |
| 2026-07-20 | 87,097 | $10.26 | $894K |
| 2026-07-17 | 5 | $10.50 | $53 |
| 2026-07-10 | 1,158 | $10.68 | $12K |
| 2026-07-06 | 5,100 | $10.96 | $56K |
| 2026-06-30 | 8,519 | $10.70 | $91K |
| 2026-06-24 | 1,507 | $10.62 | $16K |
| 2026-06-22 | 664,590 | $11.04 | $7.3M |
| 2026-06-18 | 2,336 | $11.25 | $26K |
| 2026-06-17 | 460 | $11.27 | $5K |
| 2026-06-16 | 14,012 | $11.94 | $167K |
| 2026-06-15 | 1,228 | $11.89 | $15K |
| 2026-06-12 | 630 | $11.92 | $8K |
| 2026-06-11 | 416 | $12.14 | $5K |
| 2026-06-10 | 1,410 | $12.18 | $17K |
| 2026-06-08 | 516 | $12.10 | $6K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONOver the last 90 days MED insiders reported 8 open-market buys ($1.4M) against 2 sells ($226K), so the dollar flow leans toward buying. Latest filing: Chard Daniel R (Director) on 2026-09-29.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-29 | Chard Daniel R | Director | Sell | 10K | $11.73 | $112K | 131K |
| 2026-09-28 | Chard Daniel R | Director | Sell | 10K | $11.98 | $114K | 140K |
| 2026-08-26 | Kiai Parsa | Director | Buy | 1K | $12.26 | $14K | 20K |
| 2026-08-26 | Kiai Parsa | Director | Buy | 42K | $12.26 | $515K | 707K |
| 2026-08-24 | Kiai Parsa | Director | Buy | 118 | $12.00 | $1K | 19K |
| 2026-08-24 | Kiai Parsa | Director | Buy | 4K | $12.00 | $51K | 666K |
| 2026-08-20 | Kiai Parsa | Director | Buy | 1K | $11.60 | $14K | 19K |
| 2026-08-20 | Kiai Parsa | Director | Buy | 42K | $11.60 | $487K | 661K |
| 2026-08-19 | Kiai Parsa | Director | Buy | 799 | $11.66 | $9K | 18K |
| 2026-08-19 | Kiai Parsa | Director | Buy | 29K | $11.66 | $333K | 619K |
| 2026-05-26 | Rose Jeffrey Matthew | Director | Grant | 7K | $0.00 | $0 | 18K |
| 2026-05-26 | Rose Jeffrey Matthew | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2026-05-26 | Thomas Andrea B | Director | Grant | 12K | $0.00 | $0 | 36K |
| 2026-05-26 | SCHLACKMAN SCOTT | Director | Grant | 12K | $0.00 | $0 | 42K |
| 2026-05-26 | Kiai Parsa | Director | Grant | 8K | $0.00 | $0 | 19K |
| 2026-05-26 | Kiai Parsa | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2026-05-26 | Geary Elizabeth A. | Director | Grant | 12K | $0.00 | $0 | 31K |
| 2026-05-11 | SCHLACKMAN SCOTT | Director | Buy | 3K | $12.53 | $31K | 31K |
| 2026-05-08 | SCHLACKMAN SCOTT | Director | Buy | 3K | $12.65 | $32K | 28K |
| 2026-03-25 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Grant | 11K | $0.00 | $0 | 21K |
| 2026-03-25 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Tax withholding | 862 | $9.59 | $8K | 10K |
| 2026-03-25 | Maloney James P. | Chief Financial Officer | Grant | 1K | $0.00 | $0 | 73K |
| 2026-03-25 | Maloney James P. | Chief Financial Officer | Grant | 34K | $0.00 | $0 | 72K |
| 2026-03-25 | Maloney James P. | Chief Financial Officer | Tax withholding | 3K | $9.59 | $31K | 38K |
| 2026-03-25 | Chard Daniel R | Chairman & CEO | Grant | 5K | $0.00 | $0 | 188K |
| 2026-03-25 | Chard Daniel R | Chairman & CEO | Grant | 37K | $0.00 | $0 | 183K |
| 2026-03-25 | Chard Daniel R | Chairman & CEO | Tax withholding | 20K | $9.59 | $193K | 146K |
| 2026-03-20 | Chard Daniel R | Chairman & CEO | Buy | 18K | $10.11 | $179K | 18K |
| 2026-03-17 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Tax withholding | 70 | $10.05 | $704 | 11K |
| 2026-03-17 | Maloney James P. | Chief Financial Officer | Tax withholding | 482 | $10.05 | $5K | 41K |
| 2026-03-17 | Chard Daniel R | Chairman & CEO | Tax withholding | 3K | $10.05 | $27K | 167K |
| 2026-03-13 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Tax withholding | 198 | $9.62 | $2K | 11K |
| 2026-03-13 | Maloney James P. | Chief Financial Officer | Tax withholding | 918 | $9.62 | $9K | 41K |
| 2026-03-13 | Chard Daniel R | Chairman & CEO | Tax withholding | 7K | $9.62 | $68K | 169K |
| 2025-06-25 | BROWN JEFFREY J | Director | Grant | 11K | $0.00 | $0 | 29K |
| 2025-06-25 | BROWN JEFFREY J | Director | Grant | 9K | $13.39 | $127K | 39K |
| 2025-06-25 | SCHLACKMAN SCOTT | Director | Grant | 11K | $0.00 | $0 | 26K |
| 2025-06-25 | Thomas Andrea B | Director | Grant | 11K | $0.00 | $0 | 24K |
| 2025-06-25 | Hoer Michael A. | Director | Grant | 11K | $0.00 | $0 | 26K |
| 2025-06-25 | Geary Elizabeth A. | Director | Grant | 11K | $0.00 | $0 | 20K |
| 2025-06-25 | BROWN JEFFREY J | Director | Grant | 9K | $13.39 | $127K | 39K |
| 2025-06-25 | BROWN JEFFREY J | Director | Grant | 11K | $0.00 | $0 | 29K |
| 2025-06-13 | Chard Daniel R | Chairman & CEO | Buy | 381 | $13.13 | $5K | 150K |
| 2025-03-25 | Chard Daniel R | Chairman & CEO | Grant | 125K | $0.00 | $0 | 176K |
| 2025-03-25 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Grant | 8K | $0.00 | $0 | 11K |
| 2025-03-25 | Maloney James P. | Chief Financial Officer | Grant | 24K | $0.00 | $0 | 42K |
| 2025-03-17 | Chard Daniel R | Chairman & CEO | Tax withholding | 2K | $14.35 | $27K | 51K |
| 2025-03-17 | Maloney James P. | Chief Financial Officer | Tax withholding | 438 | $14.35 | $6K | 18K |
| 2025-03-17 | MacKenzie Jonathan Barrett | VP, Finance & CAO | Tax withholding | 99 | $14.35 | $1K | 3K |
| 2025-03-16 | Chard Daniel R | Chairman & CEO | Tax withholding | 944 | $13.94 | $13K | 53K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON2 Form 144 notices on file for MED worth $226K at the prices reported; 2 in the last 90 days worth $226K. Latest: Chard Daniel R filed on 2026-09-29 to sell 9,544 shares ($112K) from 2026-09-29.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-29 | Chard Daniel ROfficer | 10K | $112K | 0.085% | 2026-09-29 | Fidelity Brokerage Services LLC |
| 2026-09-28 | Chard Daniel ROfficer | 10K | $114K | 0.085% | 2026-09-28 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON6 holders report 5% or more of MED in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Parsa Kiai at 7.1% of the class (790,693 shares), filed 2026-08-21 for an event on 2026-08-20.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-21 | 13D/Ano. 1 | Parsa Kiaiindividual, parent holding company | 791K | 7.1% | 2026-08-20 |
| 2026-08-21 | 13D/Ano. 1 | Steamboat Capital Partners, LLCinvestment adviser, other entity | 791K | 7.1% | 2026-08-20 |
| 2026-08-14 | 13G | Susquehanna Portfolio Strategies, LLCother entity | 587K | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G | Susquehanna Securities, LLCbroker-dealer, other entity | 587K | 5.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 290K | 2.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 236K | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 236K | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 233K | 2.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 53K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 53K | 0.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 53K | 0.5% | 2026-06-30 |
| 2026-08-12 | 13G/Ano. 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INCinvestment adviser | 397K | 3.6% | 2026-06-30 |
| 2026-07-29 | 13G/Ano. 19 | BlackRock, Inc.parent holding company | 327K | 2.9% | 2026-06-30 |
| 2026-05-14 | 13G/Ano. 11 | Renaissance Technologies LLCinvestment adviser | 774K | 7.0% | 2026-01-02 |
| 2026-05-14 | 13G/Ano. 11 | Renaissance Technologies Holdings Corporationparent holding company | 774K | 7.0% | 2026-01-02 |
| 2026-03-27 | 13G/Ano. 11 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-13 | 13G/Ano. 2 | Susquehanna Fundamental Investments, LLCother entity | 149K | 1.4% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 2 | G1 Execution Services, LLCbroker-dealer, other entity | 149K | 1.4% | 2025-12-31 |
13F holders
Tracked managers holding MED at their latest 13F. JSON7 of the 30 tracked managers held MED at their latest 13F, $18.2M in total at quarter-end prices. Renaissance Technologies is the largest at $8.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 779K | $8.3M | 0.01% | +5K |
| Two Sigma Investments | 2026-06-30 | 481K | $5.1M | 0.00% | +143K |
| AQR Capital Management | 2026-06-30 | 236K | $2.5M | 0.00% | +91K |
| D. E. Shaw & Co. | 2026-06-30 | 92K | $980K | 0.00% | -68K |
| Citadel Advisors | 2026-06-30 | 56K | $598K | 0.00% | new |
| Millennium Management | 2026-06-30 | 48K | $508K | 0.00% | new |
| Point72 Asset Management | 2026-06-30 | 21K | $223K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Medifast in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Medifast (MED), SEC CIK 910329, listed on NYSE, classified by the SEC as miscellaneous food preparations & kindred products. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-09-29.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-21.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-03.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-29.JSON and CSV
- Company record
- EDGAR filing index for CIK 910329Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as miscellaneous food preparations & kindred products
Other company pages
- MUMicron Technology
- NVDANVIDIA
- METAMeta Platforms
- SNDKSandisk
- SPCXSpaceX
- TSLATesla
- AAPLApple
- AMDAdvanced Micro Devices
- INTCIntel
- MSFTMicrosoft
- AMZNAmazon.com
- GOOGLAlphabet
- AVGOBroadcom
- GOOGAlphabet
- BEBloom Energy
- ORCLOracle
- DELLDell Technologies
- LITELumentum Holdings
- TSMTaiwan Semiconductor Manufacturing
- MRVLMarvell Technology
- PLTRPalantir Technologies
- NBISNebius Group
Datasets
Frequently Asked Questions
How much of MED is sold short?
What is MED's daily short volume?
Does MED have fails to deliver?
Are MED insiders buying or selling?
Have MED insiders filed to sell?
Who owns 5% or more of MED?
Which tracked 13F managers own MED?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.